Friedrich von Bohlen und Halbach

GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey

Integrated Diagnostics, Inc. operates as a molecular diagnostics firm. It develops diagnostics and measurement technologies that has a capability of measuring biomarkers for diagnosis and management of complex diseases. The company was founded by Jim Heath, David J. Galas, Leroy E. Hood, and Paul Edward Kearney and is headquartered Seattle, WA.

Curacyte AG develops and markets biopharmaceutical solutions. The firm specializes in the development of new therapeutics for acute and critical care applications. Its focus areas cover applications in hematology, antithrombosism, and oncology. Its pipeline and development portfolio encompasses technologies, such as hemoximers, distributive shock, cardiogenic shock, plasmin and plasma kallikrei, matriptase, and high-dose interleukin-2 therapy. The company was founded in February 2000 and is headquartered in Munich, Germany.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Private Life BioMed AG is a venture capital firm established in 2000 and located in Hamburg. The firm is a subsidiary of M.M. Warburg & Co. KGaA, a Hamburg-based private and investment bank.

Cosmo Holding SpA manufactures and markets pharmaceutical products. It develops technologies in the sector of modified drug release with oral, topical, and transmucosal applications. The company was founded in 1996 and is headquartered in Milan, Italy.

Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany.

dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany.

Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany.

Weinheim 216 GmbH & Co. KG operates as a cellular therapy company involving primary human hepatocytes. The company is headquartered in Weinheim, Germany.

Molecular Health AG provides clinico-molecular informatic solutions. The firm’s approach allows doctors translate patient-specific molecular and genomic data, clinical history, and published scientific evidence into drug choices. The company was founded by Friedrich von Bohlen in 2004 and is headquartered in Basel, Switzerland.

Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The private company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004.

Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA.

Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany.

Heidelberg Pharma AG provides drug development services. The firm also provides services for the pre-clinical development of new chemical or biological entities, which includes drug metabolism- and pharmacokinetic (DMPK) studies and pharmacology services in the field of cancer, inflammatory and autoimmune diseases. The company was founded in 1999 and is headquartered in Ladenburg, Germany.